Roberto Piva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3483806/publications.pdf

Version: 2024-02-01

74 papers

5,779 citations

43 h-index 79698 73 g-index

75 all docs 75 docs citations

75 times ranked 7977 citing authors

#	Article	IF	CITATIONS
1	Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies. International Journal of Molecular Sciences, 2022, 23, 4021.	4.1	3
2	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers, 2021, 13, 1235.	3.7	16
3	Genomic Instability in Multiple Myeloma: A "Non-Coding RNA―Perspective. Cancers, 2021, 13, 2127.	3.7	8
4	Biomimetic mesoporous vectors enabling the efficient inhibition of wild-type isocitrate dehydrogenase in multiple myeloma cells. Microporous and Mesoporous Materials, 2021, 325, 111320.	4.4	5
5	Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens. Blood, 2021, 138, 865-865.	1.4	0
6	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers, 2020, 12, 3855.	3.7	17
7	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nature Communications, 2020, 11, 1185.	12.8	52
8	Next Generation Sequencing (NGS) Strategies for Genetic Testing of Cerebral Cavernous Malformation (CCM) Disease. Methods in Molecular Biology, 2020, 2152, 59-75.	0.9	2
9	Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy. Cancers, 2019, 11, 563.	3.7	38
10	Integration of transcriptional and mutational data simplifies the stratification of peripheral Tâ€cell lymphoma. American Journal of Hematology, 2019, 94, 628-634.	4.1	16
11	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood, 2019, 133, 156-167.	1.4	40
12	Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature Medicine, 2019, 25, 130-140.	30.7	57
13	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia, 2018, 32, 1994-2007.	7.2	70
14	ALK expression favorably impacts the prognosis of NRASâ€'mutated metastatic melanomas. Oncology Letters, 2018, 16, 7091-7096.	1.8	1
15	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. Cancers, 2018, 10, 21.	3.7	28
16	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget, 2017, 8, 15894-15911.	1.8	84
17	The RNA-binding protein ESRP1 promotes human colorectal cancer progression. Oncotarget, 2017, 8, 10007-10024.	1.8	57
18	The heterogeneous landscape of ALK negative ALCL. Oncotarget, 2017, 8, 18525-18536.	1.8	28

#	Article	IF	CITATIONS
19	Transposable elements: The enemies within. Experimental Hematology, 2016, 44, 913-916.	0.4	1
20	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	1.4	97
21	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 744.	16.8	2
22	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 516-532.	16.8	378
23	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. Journal of Clinical Investigation, 2015, 126, 181-194.	8.2	44
24	STAT3-mediated activation of microRNA cluster 17Â92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 2014, 99, 116-124.	3. 5	50
25	Molecular events underlying interleukinâ€6 independence in a subclone of the CMAâ€03 multiple myeloma cell line. Genes Chromosomes and Cancer, 2014, 53, 154-167.	2.8	6
26	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Research, 2014, 74, 6094-6106.	0.9	45
27	Specific Induction of Akt3 in Spinal Cord Motor Neurons is Neuroprotective in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 136-148.	4.0	32
28	Nuclear Akt2 Opposes Limbal Keratinocyte Stem Cell Self-Renewal by Repressing a FOXO-mTORC1 Signaling Pathway. Stem Cells, 2014, 32, 754-769.	3.2	17
29	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693.	1.4	98
30	Gelsius: A Literature-Based Workflow for Determining Quantitative Associations between Genes and Biological Processes. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2013, 10, 619-631.	3.0	2
31	microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood, 2013, 122, 2083-2092.	1.4	84
32	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. Journal of Clinical Oncology, 2013, 31, 3019-3025.	1.6	129
33	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood, 2013, 122, 2233-2241.	1.4	45
34	ALK signaling and target therapy in anaplastic large cell lymphoma. Frontiers in Oncology, 2012, 2, 41.	2.8	39
35	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood, 2012, 120, 1274-1281.	1.4	101
36	PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113

#	Article	IF	Citations
37	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. British Journal of Haematology, 2012, 156, 354-357.	2.5	9
38	Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. Journal of Neuroscience Methods, 2012, 205, 139-147.	2.5	23
39	Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology, 2011, 47, R11-R23.	2.5	116
40	Pathobiology of Anaplastic Large Cell Lymphoma. Advances in Hematology, 2010, 2010, 1-10.	1.0	17
41	Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. Journal of Clinical Oncology, 2010, 28, 1583-1590.	1.6	152
42	Anaplastic large cell lymphoma: one or more entities among Tâ€eell lymphoma?. Hematological Oncology, 2009, 27, 161-170.	1.7	61
43	The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer, 2008, 8, 11-23.	28.4	792
44	Hypoxia transcriptionally induces macrophage-inflammatory protein-3α/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-κB. Journal of Leukocyte Biology, 2008, 83, 648-662.	3.3	46
45	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	1.4	239
46	Essential role of PDK1 in regulating endothelial cell migration. Journal of Cell Biology, 2007, 176, 1035-1047.	5.2	75
47	p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO Journal, 2007, 26, 2843-2855.	7.8	83
48	Identification and Validation of the Anaplastic Large Cell Lymphoma Signature. Advances in Experimental Medicine and Biology, 2007, 604, 129-136.	1.6	4
49	NF-κB: A Stress-Regulated Switch for Cell Survival. Antioxidants and Redox Signaling, 2006, 8, 478-486.	5.4	142
50	Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 2006, 107, 689-697.	1.4	127
51	Induction of Apoptosis in Estrogen Receptor-Negative Breast Cancer Cells by Natural and Synthetic Cyclopentenones: Role of the li®B Kinase/Nuclear Factor-ήB Pathway. Molecular Pharmacology, 2006, 70, 1812-1821.	2.3	52
52	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. Journal of Clinical Investigation, 2006, 116, 3171-3182.	8.2	139
53	15-Deoxy-Δ12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood, 2005, 105, 1750-1758.	1.4	87
54	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood, 2005, 106, $3907-3916$.	1.4	72

#	Article	IF	Citations
55	New and Old Functions of STAT3: A Pivitol Target for Individualized Treatment of Cancer. Cell Cycle, 2005, 4, 1131-1133.	2.6	111
56	Activated p38MAPK Is a Novel Component of the Intracellular Inclusions Found in Human Amyotrophic Lateral Sclerosis and Mutant SOD1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2004, 63, 113-119.	1.7	81
57	NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101, 1919-1927.	1.4	234
58	In Vivo Interference with Skp1 Function Leads to Genetic Instability and Neoplastic Transformation. Molecular and Cellular Biology, 2002, 22, 8375-8387.	2.3	53
59	S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase. American Journal of Pathology, 2002, 160, 1457-1466.	3.8	94
60	Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neuroscience Letters, 2002, 328, 125-128.	2.1	41
61	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 2002, 21, 1038-1047.	5.9	354
62	Activation of the JNK/p38 Pathway Occurs in Diseases Characterized by Tau Protein Pathology and Is Related to Tau Phosphorylation But Not to Apoptosis. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1190-1197.	1.7	159
63	Expression of Angiopoietin-1 in Human Glioblastomas Regulates Tumor-Induced Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 536-541.	2.4	50
64	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. British Journal of Haematology, 2000, $111, 263-271$.	2.5	2
65	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. British Journal of Haematology, 2000, 111, 263-271.	2.5	19
66	Lack of apoptosis in mice with ALS. Nature Medicine, 1999, 5, 966-967.	30.7	90
67	p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathologica, 1999, 98, 629-634.	7.7	32
68	S- $100\hat{l}^2$ protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neuroscience Letters, 1999, 261, 25-28.	2.1	58
69	Proteasome-dependent Degradation of p27/kip1 in Gliomas. Journal of Neuropathology and Experimental Neurology, 1999, 58, 691-696.	1.7	67
70	Characterization of MurineGirk2Transcript Isoforms: Structure and Differential Expression. Genomics, 1998, 51, 379-390.	2.9	45
71	c-Jun, JNK/SAPK Kinase and Transcription Factor NF-κB Are Selectively Activated in Astrocytes, but not Motor Neurons, in Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1314-1322.	1.7	144
72	In Situ Hybridization Analysis of Girk2 Expression in the Developing Central Nervous System in Normal and Weaver Mice. Journal of Neuropathology and Experimental Neurology, 1997, 56, 762-771.	1.7	27

ROBERTO PIVA

#	Article	IF	CITATIONS
73	bcl-2 protein expression in aged brain and neurodegenerative diseases. NeuroReport, 1994, 5, 1906-1908.	1.2	70
74	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death., 0,		3